Who invested in RECOMBINETICS

5 rounds we have observed, with the 0 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Follow RECOMBINETICS and see its new rounds in your feed. Start following

Funding summaryUpdated 5 Nov 2026

$39Mraised across 5 rounds since 2013, from 5 sources

$34MSeries A

Latest round: Series A, $34MAug 2018
Step-upi: 12.3×
Investors: 0

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

20142015201620172018

$2.0MSeries A$35KVenture$541KVenture$2.8MVenture$34MSeries A

First round: Series A, $2.0M
Biggest round: $34M
Usual gap between rounds: 15 months

The rounds

Aug 2018
Series A$34M
No investor was named in the report.
Reported by FinSMEsSEC filing: $34M sold, first sale Aug 2018
Nov 2015
Venture$2.8M
No investor was named in the report.
From a historical funding recordSEC filing: $2.8M sold, first sale Jun 2015
Oct 2014
Venture$541K
No investor was named in the report.
From a historical funding recordSEC filing: $541K sold, first sale Aug 2014
Aug 2013
Venture$35K
No investor was named in the report.
Reported by sec.govSEC filing: $35K sold, first sale Jul 2013
Jun 2013
Series A$2.0M
No investor was named in the report.
Reported by pevc.dowjones.comSEC filing: $35K sold, first sale Jul 2013

Funding filed with regulators

RECOMBINETICS filed 11 raises, $65M in all. Filings say how much was sold and to how many investors; they never name the investors.

Aug 2018$34M14 investorsequitySEC Form D
Sept 2017$83K1 investorequityof $18M offeredSEC Form D
Sept 2017$6.4M47 investorsequityof $18M offeredSEC Form D
Feb 2017$7.0M10 investorsdebt, options, securities on exerciseof $8.3M offeredSEC Form D
Oct 2016$7.7M11 investorssecurities on exercise, otherof $28M offeredSEC Form D
Jul 2016$630K7 investorsequityof $3.7M offeredSEC Form D
Jun 2015$5.7M89 investorsequityof $10M offeredSEC Form D
Jun 2015$2.8M54 investorsequityof $10M offeredSEC Form D
Aug 2014$541K25 investorsequityof $3.0M offeredSEC Form D
Jul 2013$35K125 investorsequity, securities on exerciseof $4.0M offeredSEC Form D
Mar 2012$330K13 investorsequity, securities on exerciseof $2.0M offeredSEC Form D

Founders and team

From RECOMBINETICS's own website and the SEC filings it signed: 8 on the team.

Rocco MorelliChief executive officer
Dennis WebsterDirector of Cell Culture
Daniel F. CarlsonExecutive Officeri
David F. AberleExecutive Officeri
John C. BurtisExecutive Officeri
Mitchell AbrahamsenExecutive Officeri
Scott C. FahrenkrugDirector, Promoteri
Tammy LeeExecutive Officeri

On the board, as filediBill C. FarrellJerry C. ArndtJim C. KilmanJustin F. ZenankoPeter C. HajasScott C. Rathgaber

Also claim to have backed them

This firm lists RECOMBINETICS as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.